Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis

Next Previous
X
Search
Trial Profile

Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NDV 3 (Primary) ; Aluminium hydroxide
  • Indications Vulvovaginal candidiasis
  • Focus Adverse reactions
  • Sponsors NovaDigm Therapeutics

    • Most Recent Events

    • 25 Apr 2018 Results presented in a NovaDigm Therapeutics Media Release.
    • 25 Apr 2018 According to a NovaDigm Therapeutics media release, Paul Nyirjesy Professor of Obstetrics and Gynecology and of Medicine at Drexel University College of Medicine, is the principal investigator of this study.
    • 25 Apr 2018 Results of post hoc exploratory analysis evaluating an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin protein for prevention of Recurrent Vulvovaginal Candidiasis published in the Clinical Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top